Abstract
Chronic bacterial prostatitis (CBP) is, usually, caused by uropathogens, especially gram-negative bacilli, although infection is sometimes due to Gram-positive and atypical microorganisms. A recent increasing in prevalence of Gram-positive strains has been reported. The aim of this study was to explore the epidemiological features and resistance rates in uropathogens isolated from CBP outpatients in last 10 years. All consecutive outpatients with demonstrated CBP attending a single Sexually Transmitted Disease centre from January 1997 and December 2008, were enrolled and underwent microbiological cultures in first void early morning urine, midstream urine, expressed prostatic secretion, and post prostate massage urine. Prevalence of different bacterial strains was stratified in four different periods: 1997–1999, 2000–2002, 2003–2005, 2006–2008. Any changes observed in epidemiological features and resistance rates in uropathogens over the whole study period have been analyzed. The present study has been planned, thus, as in vitro study. From 6,221 patients, 4,601 Gram-positive and 1,620 Gram-negative bacterial strains have been isolated. Enterococcus faecalis and Escherichia coli strains are the first and second frequent pathogens found, respectively. Significant differences between E. faecalis prevalence in the 1997–1999 and 2006–2008 periods were found. E. coli showed a significant difference between prevalence in 1997–1999 and 2006–2008 periods. Gram-positive organisms showed a decreasing of susceptibility to ciprofloxacin as well as Gram-negative strains, while a good susceptibility to the levofloxacin was evidenced. E. faecalis prevalence seemed to be raised in 2006–2008 periods. Moreover, a decreasing of activity of ciprofloxacin and a good activity profile of levofloxacin have been reported.
Similar content being viewed by others
References
Arslan, H., O.K. Azap, O. Ergönül, and F. Timurkaynak. 2005. Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. 56, 914–918.
Bundrick, W., S.P. Heron, P. Ray, W.M. Schiff, A.M. Tennenberg, B.A. Wiesinger, P.A. Wright, S.C. Wu, N. Zadeikis, and J.B. Kahn. 2003. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 62, 537–541.
Drusano, G.L., S.L. Preston, M. Van Guilder, D. North, M. Gombert, M. Oefelein, L. Boccumini, B. Weisinger, M. Corrado, and J. Kahn. 2000. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob. Agents Chemother. 44, 2046–2051.
Ena, J., F. Arjona, C. Martínez-Peinado, M.M. López-Perezagua, and C. Amador. 2006. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68, 1169–1174.
Fowler, J.E. Jr. 2002. Antimicrobial therapy for bacterial and nonbacterial prostatitis. Urology 60, 24–26.
Giubilei, G., N. Mondaini, A. Crisci, A. Raugei, G. Lombardi, F. Travaglini, G. Del Popolo, and R. Bartoletti. 2005. The Italian version of the National Institutes of Health chronic prostatitis symptom index. Eur. Urol. 47, 805–811.
Krieger, J.N. 2004. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol. Nefrol. 56, 99–107.
Krieger, J.N., S.W. Lee, J. Jeon, P.Y. Cheah, M.L. Liong, and D.E. Riley. 2008. Epidemiology of prostatitis. Int. J. Antimicrob. Agents 31, 85–90.
Krieger, J.N., L. Nyberg, Jr., and J.C. Nickel. 1999. NIH consensus definition and classification of prostatitis. JAMA 282, 236–237.
Krieger, J.N. and D.E. Riley. 2004. Chronic prostatitis: Charlottesville to Seattle. J. Urol. 172, 2557–2560.
Krieger, J.N., D.E. Riley, P.Y. Cheah, M.L. Liong, and K.H. Yuen. 2003. Epidemiology of prostatitis: new evidence for a world-wide problem. World J. Urol. 21, 70–74.
Mazzoli, S. 2007. Conventional bacteriology in prostatitis patients: microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch. Ital. Urol. Androl. 79, 71–75.
Mazzoli, S. 2010. Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications. FEMS Immunol. Med. Microbiol. Article in press.
Mazzoli, S., T. Cai, V. Rupealta, A. Gavazzi, R.C. Pagliai, N. Mondaini, and R. Bartoletti. 2007. Interleukin 8 and anti-chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur. Urol. 51, 1385–1393.
McNaughton-Collins, M., G.F. Joyce, T. Wise, and M.A. Pontari. 2007. Prostatitis. In M.S. Litwin and C.S. Saigal (eds.). Urologic Diseases in America. US Department of Health and Human Services, Public Health Taylor et al. p. 6 Am J Med. Author manuscript; available in PMC 2009 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript Service, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 07-5512. US Government Publishing Office, Washington, DC, USA.
Motrich, R.D., C. Cuffini, J.P. Oberti, M. Maccioni, and V.E. Rivero. 2006. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. J. Infect. 53, 175–183.
Murphy, A.B., A. Macejko, A. Taylor, and R.B. Nadler. 2009. Chronic prostatitis: management strategies. Drugs 69, 71–84.
Naber, K.G. 2008. Management of bacterial prostatitis: what’s new? BJU Int. 101, 7–10.
Naber, K.G., B. Bergman, M.C. Bishop, T.E. Bjerklund-Johansen, H. Botto, B. Lobel, F. Jinenez Cruz, F.P. Selvaggi, and Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). 2001. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur. Urol. 40, 576–588.
Nickel, J.C., R.B. Alexander, A.J. Schaeffer, J.R. Landis, J.S. Knauss, and K.J. Propert. 2003. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J. Urol. 170, 818–822.
Nickel, J.C. and J. Xiang. 2008. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J. Urol. 179, 1391–1395.
Potts, J. and R.E. Payne. 2007. Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key. Cleve. Clin. J. Med. 74, 63–71.
Schaeffer, A.J. 2006. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N. Engl. J. Med. 355, 1690–1698.
Türk, S., P. Korrovits, M. Punab, and R. Mändar. 2007. Coryneform bacteria in semen of chronic prostatitis patients. Int. J. Androl. 30, 123–128.
Wagenlehner, F.M., T. Diemer, K.G. Naber, and W. Weidner. 2008a. Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Andrologia 40, 100–104.
Wagenlehner, F.M., A.H. Niemetz, W. Weidner, and K.G. Naber. 2008b. Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994–2005. Int. J. Antimicrob. Agents 31, 25–34.
Walz, J., P. Perrotte, G. Hutterer, N. Suardi, C. Jeldres, F. Bénard, L. Valiquette, and P.I. Karakiewicz. 2007. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int. 100, 1307–1311.
Weidner, W., T. Diemer, P. Huwe, H. Rainer, and M. Ludwig. 2002. The role of Chlamydia trachomatis in prostatitis. Int. J. Antimicrob. Agents 19, 466–470.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cai, T., Mazzoli, S., Meacci, F. et al. Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis. J Microbiol. 49, 448–454 (2011). https://doi.org/10.1007/s12275-011-0391-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-011-0391-z